NCT02493816View on ClinicalTrials.gov

Safety Study of Gene-modified Autologous Fibroblasts in Recessive Dystrophic Epidermolysis Bullosa

PHASE1CompletedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

September 30, 2015

Primary Completion Date

March 31, 2018

Study Completion Date

March 31, 2018

Conditions
Recessive Dystrophic Epidermolysis Bullosa
Interventions
DRUG

Gene-modified autologous fibroblasts

3 intradermal injections of COL7A1 gene-modified autologous fibroblasts will be administered on day 0 only.

Trial Locations (1)

SE1 9RT

Guy's and St Thomas' NHS Foundation Trust, London

All Listed Sponsors
collaborator

University College, London

OTHER

lead

King's College London

OTHER

NCT02493816 - Safety Study of Gene-modified Autologous Fibroblasts in Recessive Dystrophic Epidermolysis Bullosa | Biotech Hunter | Biotech Hunter